|Opportunity Title||Description||Read More|
|Biomarker panel for Triple Negative Breast Cancer||
Novel panels of epigenetic biomarkers for (1) diagnosis of triple negative breast cancer and detection of minimal residual disease; and (2) predicting prognosis of patients with triple negative breast cancer.
|Read more – View or download the flyer|
|Anticancer antibody targeting NPY & PYY||A humanised monoclonal antibody functioning via a novel mechanism of action that effectively neutralizes NPY/PYY, reducing tumour growth and increasing survival in animal tumour models. The antibody has a dual effect; directly targeting the tumour in addition to modulation of the immune system.||Read more – View or download the flyer|
|New target for insulin resistance & Type-2 Diabetes: PKCε||The lipid-regulated protein kinase C isoform, PKCε, plays a central role in β-cell dysfunction. Inhibition of PKCε corrects multiple dysfunctions associated with type-2 diabetes - including increasing glucose stimulated insulin secretion - with minimal side effects, providing unique benefits over existing therapies.||Read more – View or download the flyer|
|Novel marker for diagnosis of ovarian cancer||A novel diagnostic biomarker for the detection of ovarian cancer. Hyper-methylation of LOC134466 - indicative of the presence of cancer and measurable in blood measured – is candidate marker for early detection and post-surgical surveillance or monitoring the success of treatment and relapse/recurrence of disease.||Read more – View or download the flyer|